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A complete mutation screen of the ADPKD genes by DHPLC. The disease is progressive with cyst development and
Background. Genetic analysis is a useful diagnostic tool in enlargement resulting in bilateral polycystic kidneys and
autosomal dominant polycystic kidney disease (ADPKD), es- ESRD, typically in late middle age. ADPKD is geneti-pecially when imaging results are equivocal. However, molecu-
cally heterogeneous with two genes, PKD1 (chromosomelar diagnostics by direct mutation screening has proved difficult
region 16p13.3) and PKD2 (4q21) identified and charac-in this disorder due to genetic and allelic heterogeneity and
complexity of the major locus, PKD1. terized, plus evidence of rare unlinked families [1–5].
Methods. A protocol was developed to specifically amplify PKD1 accounts for approximately 85% of cases and is
the exons of PKD1 and PKD2 from genomic DNA as 150 to associated with a more severe disease course (average450 bp amplicons. These fragments were analyzed by the tech-
age at onset of ESRD of 53 compared to 69 years fornique of denaturing high-performance liquid chromatography
(DHPLC) using a Wave Fragment Analysis System (Transge- PKD2 [6]). The PKD1 and PKD2 genes encode related
nomics) to detect base-pair changes throughout both genes. proteins, polycystin-1 and -2, respectively, which proba-
DHPLC-detected changes were characterized by sequencing. bly form part of a receptor/channel complex involved in
Results. Cost effective and sensitive mutation screening of
regulating intracellular Ca2 levels [7].the entire coding regions of PKD1 and PKD2 by DHPLC was
Presymptomatic diagnosis of ADPKD is possible byoptimized. All base-pair mutations to these genes that we pre-
viously characterized were detected as an altered DHPLC pro- various imaging methods (abdominal ultrasound, com-
file. To assess this method for routine diagnostic use, samples puter tomography and magnetic resonance) and is rela-
from a cohort of 45 genetically uncharacterized ADPKD pa- tively reliable in adult patients, especially in the moretients were analyzed. Twenty-nine definite mutations were de-
severe PKD1. However, there is a role for genetic diag-tected, 26 PKD1, 3 PKD2 and a further five possible missense
nosis in this disorder, especially in patients with equivocalmutations were characterized leading to a maximal detection
rate of 76%. A high level of polymorphism of PKD1 also was imaging results, those with a negative family history and
detected, with 71 different changes defined. The reproducibility in cases where a definite diagnosis is required in younger
of the DHPLC profile enabled the recognition of many com-
individuals, such as for living related kidney donors. Ge-mon polymorphisms without the necessity for re-sequencing.
netic diagnosis by linkage analysis is possible but is ofConclusions. DHPLC has been demonstrated to be an effi-
cient and effective means for gene-based molecular diagnosis limited utility due to the requirement for a relatively
of ADPKD. Differentiating missense mutations and polymor- large family with multiple diagnosed members, to deter-
phisms remains a challenge, but family-based segregation anal- mine the gene involved.ysis is helpful.
Mutation analysis would be a more direct method of
genetic diagnosis and allow genotype/phenotype correla-
tions to be studied. However, mutation screening has
Autosomal dominant polycystic kidney disease
proven uniquely difficult in ADPKD. The PKD1 tran-(ADPKD) is a common genetic disease of the kidney
script is large, encoded by 46 exons, and embedded in(frequency 1/1000) accounting for approximately 5% of
a complex duplicated genomic area [1, 2]. The 5 regionend-stage renal disease (ESRD) in Western countries.
of PKD1, from upstream of exon 1 to exon 33, is reiter-
ated at least five times further proximally on the same
chromosome. As this reiteration is relatively recent inKey words: autosomal dominant polycystic kidney disease, PKD1,
PKD2, mutations, denaturing high-performance liquid chromatography. evolutionary time, only approximately 2% sequence di-
vergence exists between the PKD1-like pseudogenesReceived for publication October 15, 2001
(HG loci) and PKD1, complicating specific amplificationand in revised form December 19, 2001
Accepted for publication December 20, 2001 of the disease gene [8]. In addition to these structural
problems, the genetic heterogeneity and marked allelic 2002 by the International Society of Nephrology
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heterogeneity at PKD1 and PKD2, with most mutations FIGE Mapper Electrophoresis System (Bio-Rad, Herts,
unique to a single family [9, 10], have further complicated UK). Gels were Southern blotted and hybridized with
direct mutation based genetic diagnosis. Although, sev- the PKD1 IVS1 probe CW10, as previously described [1].
eral screens of the entire approximately 3kb coding re-
PCR amplification and generation ofgion of PKD2 have been described [10–12], only limited
DHPLC ampliconsanalyses of the duplicated part of PKD1 have been pub-
lished. These studies have used methods of long-poly- The duplicated region of PKD1 was amplified as five
merase chain reaction (PCR), with primers anchored in PCR fragments that were either anchored in single copy
single copy DNA, and PKD1 specific-PCR, exploiting the DNA or mismatched with HG sequence (details are in
rare differences between the PKD1 and HG loci, to ana- the Results section and Table 1). Long-PCR fragments
lyze the duplicated region [9, 13–19]. To date, only one (3kb) were amplified as previously outlined [9] using
screen of the entire PKD1 gene has been described, show- the rTth DNA polymerase (PE Applied Biosystems) in
ing a mutation detection rate of approximately 50% [9]. the supplied DMSO containing buffer. A combination
However, the methods used in that study, including the of Amplitaq (PE Applied Biosystems, Foster City, CA,
use of mRNA derived template and the protein trunca- USA) and Taq Extender (Stratagene, Heidelberg, Ger-
tion test, are such that the strategy is not readily adapted
many) was used for the GC-rich exons 1 of PKD1 andfor routine diagnostic needs.
PKD2 [9]. Each amplicon for DHPLC analysis was am-Recently, a new semi-automated method has been in-
plified as a fragment of 150 to 450 bp using Amplitaqtroduced for mutation analysis in human genes, denatur-
and the supplied (non-DMSO) buffer for PKD2 and aing high-performance liquid chromatography (DHPLC)
dimethyl sulfoxide (DMSO) containing buffer for PKD1[20, 21]. This system is based on the differential adsorp-
(detailed in Tables 2 and 3 and [9, 24]). The primerstion of homo- and hetero-duplexes to a hydrophobic ma-
were positioned approximately 20 to 30 bp from thetrix in a chromatographic column. Amplicons with a mis-
intron-exon boundary to allow the detection of splicingmatch have decreased interaction with the matrix and are
defects but minimize intronic polymorphism. Due to thethus eluted earlier than the normal amplicon, resulting in
presence of a frequent intronic deletion (IVS928del7,an alteration of the elution profile. This method has a
found in 8 of 46 samples), a second reverse primer (9high level of sensitivity and specifically, is semi-auto-
int), positioned only 2 bp from the intron/exon boundary,mated and does not require analysis by electrophoresis.
was used to screen samples carrying the deletion poly-Due to the advantages of this technique it has now be-
morphism. The availability of a known mutation of thiscome the method of choice for screening large and multi-
exon genes involved in human genetic disease [22]. splice site (IVS9 1G→T) was used to show the utility
In the current study, we describe a mutation screen of the closer primer.
of the entire PKD1 and PKD2 genes by DHPLC us- Heteroduplexes of amplicons were generated by heat-
ing genomic DNA from a cohort of 45 ADPKD patients. ing the PCR products at 95C for three minutes, cooling
An overall detection rate of approximately 70% was 0.1C per second to 65C, incubating at 65C for 30 min-
achieved. We propose this approach as an efficient and utes, cooling 0.1C per second to 37C, with a final incu-
effective way to perform molecular diagnostics in ADPKD. bation of 10 minutes.
DHPLC and gradient generationMETHODS
Denaturing high-pressure liquid chromatography wasSelection of the cohort
performed using the Wave system (Transgenomic Inc.,
Forty-five unrelated ADPKD probands were selected Omaha, NE, USA). Crude PCR product, sufficient to
for screening. Informed consent was obtained from each generate an elution peak of 3 to 5mV (200 to 500 ng, inparticipant and the study was approved by the appro-
Buffer C), was injected into a preheated, fully equilibratedpriate IRB and/or Ethics Committee. This cohort con-
chromatographic column (C18 reverse-phase, non-poroussisted of typically sized families that had not previously
polystyrene-divinyl benzene matrix; DNASep Column;been subjected to linkage analysis. All probands in the
Trangenomic Inc.). A linear gradient of 5% triethylam-study met established ultrasound criteria for ADPKD di-
monium acetate (TEAA) (Buffer A) and 25% acetoni-agnosis [23]. A blood sample for DNA isolation was drawn
trile  5% TEAA (Buffer B) with a flow rate of 0.9 mL/from each proband and from available family members
min was generated for each amplicon. Each DHPLC runinterested in participating.
included a DNA loading step (5% drop for loading of
DNA isolation and field inversion gel Buffer B), a linear separation gradient (2% Buffer B
electrophoresis (FIGE) slope per min, 4.5 min), a wash step (75% acetonitrile;
Buffer D, 0.5 to 1 min) and an equilibration step (0.9 toGenomic DNA was extracted by standard phenol-
1.2 min). When DMSO buffer was used in the PCRchloroform procedures. An aliquot of DNA (5 g) was
digested with EcoRI and separated by FIGE using the reaction, longer wash and equilibration steps were re-
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Table 1. PKD1 specific fragments
Annealing
temperatures Positiona Size
Fragment Primers (5-3) C (nt) bp Exons
Gen 1 [9] 64 2033–4310 2278 1
Gen 2–12 CCAGCTCTCTGTCTACTCACCTCCGCATC 68 17,647–26,372 8726 2–12
CCACGGTTACGTTGTAGTTCACGGTGACG
Gen 13–15 [17] 70 26,246–30,631 4386 13–15
Gen 15–21 [17] 68 30,603–33,980 3378 15–21
Gen 22–34 CCGTGTAGAGAGGAGGGCGTGTGCAAGGA 70 36,883–44,383 7501 22–34
TCGGCAAGGACCTGCTGGATCAGGTCTTC
a Genomic DNA (Accession No. L39891)
quired. Total run times were therefore 9.4 minutes and ter. An aliquot of the product (30 to 180 ng) was com-
8.6 minutes for the PKD1 and PKD2 amplicons, respec- bined with each primer (3.2 pmol) and DMS0 (1 L)
tively. for sequencing reactions, analyzed on an ABI377 se-
quencing machine and assembled using Sequencher 3.1.1
Fragment melting profile analysis and optimization of software.
DHPLC conditions
Validation of mutationsThe melting profile of each fragment was analyzed
using the Wavemaker version 4.0.32 (Transgenomic Inc.) To analyze the segregation in families of characterized
software. The process by which the melting point is deter- mutations the DHPLC elution profiles of all family mem-
mined is based on the Fixman and Friere implementation bers (always including two affected cases from different
of Poland’s algorythmn [25], which calculates the proba- generations) were compared. Due to the reproducibility
bility that a base is in the helical duplex form or the non- of the elution profile, the mutant genotype was assigned
helical, single-stranded form. to samples resembling the mutant profile. When more
DHPLC conditions for each amplicon were optimized than one sequence change was present in the same frag-
by use of the available positive controls (details are in ment, validation was performed by direct sequencing of
Tables 2 and 3). Each fragment was eluted at the pre- all samples. Missense mutations were screened on 146
dicted melting temperature, and plus and minus 1 and normal chromosomes by DHPLC.
2C. If multiple domains were predicted by the Wave-
maker software, then a wider range of temperatures was
RESULTStested and the final analysis performed under two sets
of conditions (see Tables 2 and 3 for the final conditions DHPLC analysis of the ADPKD genes
for each fragment). A set of eight random samples, plus
A method was developed to screen the entire PKD1the positive control, were used for each optimization
and PKD2 genes from genomic DNA by DHPLC. Theprocess and conditions were adjusted so that the DNA
duplication of the PKD1 genomic region (exons 1 toeluted from the column at, or greater than, four minutes.
33) required that first-round long-PCR reactions wereResolution was optimized so that the elution profile of
necessary to specifically amplify these exons. This wasthe positive control differed most from the normal sam-
achieved for the regions bordering single copy DNA byple. When no positive control was available, conditions
employing a primer anchored in single copy DNA; thewere considered to be optimal at the temperature and
method used to amplify exon 1 and exons 22 to 34 hascorresponding gradient immediately before a significant
previously been described (Table 1 and Fig. 1) [9]. Fordecrease in the retention time of the amplicon was ob-
the rest of the duplicated area, specific amplification ofserved and/or an excessive broadening of the peak, indi-
PKD1 was obtained by employing primers that matchedcating excess denaturation. This temperature was typi-
differences between PKD1 and HG sequences. Two pre-cally located in the range of 50 to 75% helical fraction
viously described primer pairs exploiting a number offor the amplicons analyzed.
mismatches in exon 15 were used to amplify exons 13
DNA sequencing to 21 [17]. To analyze exons 2 to 12, one primer was
positioned in the region of IVS1 that is deleted in mostSamples showing an aberrant elution profile were re-
copies of the HG [8] and the second in exon 13, whichamplified and subjected to direct sequencing using the
is not present in the IVS1-containing HG locus (manu-Big-Dye Terminator kit (PE Applied Biosystems). The
script in preparation). The specificity of these productsPCR product was purified by polyethylene glycol 8000
(PEG) and ethanol precipitation and resuspended in wa- was determined by amplification of somatic cell hybrids
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Fig. 1. Map of the PKD1 gene showing the fragments employed for specific amplification of the duplicated part of the gene (top) and the locations
of detected mutations in the indicated pedigrees (bottom; details are in Table 4). The mutation types are: I/F, in-frame deletion; M, missense; N,
nonsense; F/S, frame-shifting deletion/insertion; and S, splicing.
containing either just PKD1 (radiation hybrid Hy145.19) fragment. The analysis of positive controls also permitted
the sensitivity of the method to be assessed. All of ouror only the HG loci (P-MWH2A) [1].
All exons were amplified as fragments of 150 to 450 previously described base-pair mutations and polymor-
phisms [9] were detected with the amplicons and analysisbp, a size range found to be ideal for DHPLC analysis
(Tables 2 and 3). For the duplicated region, the PKD1- conditions described in our current study, indicating that
DHPLC is a very sensitive method for detecting base-specific first-round product was used as the template,
while for the remainder of PKD1 and for PKD2, DHPLC pair changes.
amplicons were amplified directly from genomic DNA.
Mutation screening by DHPLC in a cohort ofLarge exons were split into more than one fragment
ADPKD patients(exon 15 was analyzed as 13 overlapping fragments) and
intronic primers located 25 to 30 bp from the intron/ To determine the achievable detection rate, a cohort
exon boundaries. The 15 PKD2 exons were amplified of 45 uncharacterized ADPKD patients was analyzed.
using previously described primer pairs and conditions Initial screening of PKD1 for large-scale rearrangements
(Table 3) [24]. In total PKD1 was amplified as 64 frag- by FIGE did not identify any mutations. The entire cod-
ments and PKD2 as 17, making a total of 81 to analyze ing regions of both the PKD1 and PKD2 genes (or until a
both genes. clear mutation was identified) were screened by DHPLC.
The temperatures and initial Buffer B concentration A total of 266 aberrant profiles were detected and char-
of the elution gradient for DHPLC analysis were deter- acterized, illustrating the variable nature of the PKD1
mined for each of the amplicons using the Wavemaker gene. In the 32 patients in whom both genes were fully
software and empirically (Methods section; Tables 2 screened, an average of 5.4 DNA changes (range 0 to
and 3). Analysis temperatures for PKD1 were generally 14) were found per patient. These changes were charac-
higher than for PKD2, reflecting the higher GC content. terized by sequencing, and segregation with the disease
If the melting profile of the fragment was reasonably was analyzed when samples from other family members
homogenous one analysis temperature was used. How- were available. Figures 2 and 3A show examples of aber-
ever, for 14 PKD1 and 8 PKD2 fragments, two different rant DHPLC profiles from analyses of the PKD1 and
melting domains were detected and, in these cases, the PKD2 genes and examples of sequencing are shown in
amplicon was analyzed under two different sets of condi- Figure 4. The way in which the reproducibility of the
tions (Tables 2 and 3). An important determinant for DHPLC profile was used to trace the mutation within a
establishing ideal DHPLC conditions was the availability family is illustrated in Figure 3B.
of positive controls. Previously characterized mutations Of the total changes, 29 were definite mutations, 26
from PKD1 and 3 from PKD2, consisting of 13 nonsenseor polymorphisms were available as positive controls for
58/64 PKD1 and 15/17 PKD2 amplicons (Tables 2 and 3). mutations, 12 truncating deletions and/or insertions, a
large and a small in-frame deletion and 2 splicing defectsThese controls included a variety of changes, but the
most subtle change (a substitution) was selected if avail- (Table 4). One of these mutations, 5225delAG (a pre-
viously described mutation; [15]) was found in two fami-able. As well as helping to determine ideal analysis condi-
tions, the positive controls also allowed the quality of lies, while two nonsense mutations, Q1838X and S2164X
were present in the same patient and found to be inher-analysis to be monitored by inclusion with each run of the
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Table 3. Details of PKD2 amplicons
DHPLC conditions
Exonic Size Temp. Initial % Positive
fragment bp C buffer B controls
1a 279 69, 71 54 R28P
1b 291 67, 69 54 None
1c 220 69 51 IVS11G→C
2 188 56, 57 50, 48 W201X
3 268 57, 60 54, 52 V262M
4 365 60 56 R361X
5 362 57 56 G381R
6 298 58 54 1417delC
7 318 51, 57 55, 53 Q555X
8 292 56, 58 54 1782delC
9 217 55 51 IVS91G→C
10 216 56 50 2075insCG
11 235 57 52 2125delC
12 195 59 50 Y762X
13 235 60 52 E814X
14 248 61, 63 52 R872X
15 382 58, 60 56 None
ited on the same chromosome from the affected father.
In this case it is not clear if both mutations occurred
simultaneously or if a second mutation occurred on an
already mutant allele. In total, definite mutations were
identified in 29 of 45 pedigrees (64%). Samples were
available to show segregation with the disease in 16 of
these pedigrees.
A second group of probable mutations were defined,
consisting of non-conservative missense changes in which
segregation with the disease was demonstrated. These
changes were not found on 146 normal, unrelated chro-
mosomes or previously described as a polymorphism.
Two mutations fitted this category, Y2092C, a change in
the 16th PKD repeat and L3851P a previously described
[26] substitution in the 3rd extracellular loop in the trans-
membrane region. Leucine 3851 is a highly similar valine
in polycystin-1 orthologs in mouse and Fugu fish, while
tyrosine 2092 is conserved in the C- strand of many
PKD repeats [27] and also found at this position in the
mouse, although it is a cysteine in Fugu [28]. Two further
non-conservative missense changes: R1340W (PKD re-
peat 7 and conserved as a positively charged histidine
in mouse and Fugu) and E1811K (PKD repeat 12, con-
served as a negatively charged glutamic acid or aspartic
acid in mouse and Fugu) were characterized. Neither of
these changes was found in the cohort of normal indi-
viduals or has previously been described, however, due
to the lack of available samples, segregation could not
be tested. Finally, a conservative change, I3167F, which
has not been found on normal chromosomes, but where
segregation could not be demonstrated, was identified.
This residue is an isoleucine in mouse and Fugu and lies
within the possible lipid binding PLAT domain [29].
Although it is difficult to prove if these substitutions are
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mutations, it is worth noting that the entire coding region
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Fig. 2. Examples of aberrant denaturing high-pressure liquid chromatography (DHPLC) profiles obtained from analysis of PKD1 exon fragments,
as indicated.
of PKD1 and PKD2 was screened and these were the only final false positive rate that decreased as optimal analysis
likely pathogenic changes detected. Inclusion of the seg- of each fragment was achieved during the study.
regating missense changes increases the overall detection
rate to 69%, while inclusion of all the possible missense
DISCUSSIONsubstitutions shows a mutation detection rate of 76%.
In addition to the mutations, and reflecting the fre- This study describes the first screen of the entire PKD1
quency of DHPLC profile changes, a high level of poly- and PKD2 genes for mutation. A largely genetically un-
morphism was detected. Seventy-one different polymor- characterized cohort of ADPKD patients was analyzed,
phic changes to PKD1 and two PKD2 polymorphisms similar to that which may be seen in a routine diagnostic
were detected (Table 5). Thirty-four of these have been setting. The method employed, DHPLC, has proven suit-
described in previous studies, leaving 53% as newly char- able for rapid detection of base pair changes with an
acterized changes. The changes were defined as polymor- overall detection rate of approximately 70%.
phisms because they were intronic changes beyond the
DHPLC is becoming the method of choice for analyz-
splice consensus sites (N  14), in the 3 UTR (N  1),
ing large multi-exon genes, such as those causing cysticsilent exonic changes (not altering an amino acid) (N 
fibrosis and tuberous sclerosis [30–32], because of the35) or amino acid substitutions that did not segregate
semi-automation of the analysis, the high level of sensi-with the disease in this or previous studies (N 21). These
tivity (100% of the known mutations in this study) andpolymorphisms are clearly a complication to mutation
the cost of analysis, calculated at $1 per sample runanalysis in PKD1. However, because of the reproducible
[31]. While direct sequencing may be considered the bestnature of the DHPLC profile (demonstrated by the segre-
means to analyze small genes (with few exons) [33],gation analysis; Fig. 3B), frequent polymorphisms, once
larger more complex genes benefit from a screening ap-identified by sequencing, were recognized in subsequent
proach, such as DHPLC, to flag abnormal exons, whichsamples by DHPLC “signature-based” genotyping. A
thus decreases the number of exons to be sequenced, andtotal of 54 (20%) DHPLC false positives were detected
hence the total cost of the analysis. This consideration isin the screen of 45 patients, in which no sequence change
was identified. This, however, probably overestimates the of particular importance when selecting a method for
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Fig. 3. (A). Examples of aberrant DHPLC ob-
tained from analysis of PKD2 exon fragments,
as indicated. (B; top) Segregation analysis of
the mutation Q2158X; found in the proband
(2116) and affected father (2115) but not nor-
mal control and (bottom) S2164X; present in
the proband (1565) and her affected father
(1590), but not unaffected brother (1652) or
control.
Fig. 4. Examples of sequence data showing:
(A) nonsense mutation Q266X; 1007C→T;
(B) missense change Y2092C; 6486A→G and
(C ) insertion, 12521insA.
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Table 4. Details of mutations
Mutation Exon Amino acida/ Segregationb
designation fragment DNA change Pedigree demonstrated Reference
PKD1
285GC→A 1a 24↓ 88 Yes Novel
319insCC 1a 36↓ 382 NP Novel
C230X 5a 901C→A 381 NP Novel
Q266X 5c 1007C→T 241 NP Novel
R1340W 15c 4229C→T 366 NP Novel
4804del252 15e 1532-1615 375 NP Novel
Q1636X 15f 5117C→T 433 Yes Novel
5225delAG 15f 1671↓ 206,376 Yes; NP [15]
E1811K 15g 5642G→A 436 NP Novel
Q1828X 15h 5693C→A 293 Yes Novel
W1837X 15h 5722G→A 379 NP Novel
Y2092C 15l 6486A→G 352 Yes Novel
6651del28 15m 2144↓ 86 Yes [9, 16]
Q2158X 15m 6683C→T 438 Yes Novel
R2163X 15m 6698C→T 449 Yes [9]
S2164X 15m 6702C→G 293 Yes Novel
I2260del 15n 6989del3 239 Yes Novel
IVS161G→C 16 2306-2355 450 Yes Novel
Q2376X 17 7337C→T 602 NP Novel
7596del10 18 2461↓ 372 NP Novel
8531delC 23a 2773↓ 377 Yes Novel
Y2991X 25 9184C→G 423 Yes Novel
I3167F 27 9710A→T 439 NP Novel
Q3473X 34 10628C→T 385 NP Novel
11192delC 37 3660↓ 386 NP Novel
Y3780X 40 11551C→G 174 Yes Novel
IVS40-1G→A 41 3804-3845 417 NP Novel
L3851P 42 11763T→C 341 Yes [26]
12474delGG 45 4087↓ 374 NP Novel
12521insA 45 4101↓ 243 NP Novel
12617delC 45 4135↓ 373 NP [9]
PKD2
189delC 1a 63↓ 353 Yes Novel
2073insCG 10 691↓ 338 Yes Novel
E814X 13 2440G→T 283 Yes Novel
a Symbols are: ↓, truncated after; , amino acids deleted (inclusive)
b NP, segregation analysis not possible because of lack of family members or available samples
routine molecular diagnostics where high throughput tection rate (using positive controls) and an increased
rate of false positives in fragments greater than 450 bp.and cost considerations are important.
The results of this screen have illustrated the sensitiv- Consequently, although larger fragments would have been
beneficial to minimize the number of analyses for largeity of DHPLC with all previous changes detected and
the majority of new changes being simple substitutions. exons (like exon 15), amplicons of no larger than 450
bp were employed.The position of the change within the amplicon did not
influence the detection rate, as in some other conforma- Conditions for DHPLC were determined using the
Wavemaker 4.0.32 software, but for some regions weretion sensitive systems (such as SSCA and gel-based het-
eroduplex analysis [34]), with substitutions detected im- also calculated employing a Stanford University Web based
site, Stanford Melt program (http://insertion.stanford.edu/mediately adjacent to the primer (for example, see exon
9 in the Methods section). This allowed the use of primers melt.html). Although the predictions were generally sim-
ilar, for some amplicons the WM4.0.32 program pre-just 20 to 30 bp from the intron/exon boundaries, min-
imizing the detection of intronic polymorphisms. Initial dicted significantly higher temperatures and in general
we had greatest success with these calculations. For aanalysis of the single copy exons of PKD1 with pre-
viously described primers located 40 to 60 bp from the few fragments, neither prediction was accurate and in
these cases the availability of positive controls was in-splice sites [35] showed an unacceptably high level of vari-
ant profiles due to intronic changes. Our screen of the valuable for establishing optimal analysis conditions.
A particular problem that was previously evident inADPKD genes also has allowed the optimal size of
amplicons to be analyzed. Previous studies have sug- mutation screens of PKD1, but emphasized in this study
of the entire gene for base-pair changes, is the level ofgested optimal sizes for DHPLC analysis of 150 to 700
bp [22], however, we found a significant decrease in de- polymorphism [9, 16, 36]. In cases where the entire gene
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Table 5. Description of polymorphisms
cDNA change or
Designation amino acid position Location Frequency % Reference
P/L61 393C/T EX1 4 Novel
1330C/T L373 EX5 10 [9]
1420C/T H403 EX6 2 [9]
IVS626C/T IVS6 2 Novel
IVS7-27C/T IVS7 2 Novel
1921C/T H570 EX8 4 [9]
P/S572 1925C/T EX8 2 Novel
IVS928del7 IVS9 16 Novel
IVS9-4A/G IVS9 33 Novel
2320C/T H703 EX11 2 Novel
2905A/C A898 EX11 8 [16]
2911G/A P900 EX11 4 [16]
2941C/T D910 EX11 4 [16]
3025G/A T938 EX11 2 Novel
IVS11-5C/T IVS11 2 Novel
3274C/T G1021 EX13 14 [16]
3322A/G L1037 EX13 8 [16]
M/T1092 3486T/C EX14 8 Novel
3583C/T A1124 EX15 6 [16]
3586C/T S1125 EX15 6 [16]
P/S1168 3713C/T EX15 2 Novel
W/R1399 4406T/C EX15 4 [16]
4474C/T A1421 EX15 2 Novel
5047G/A T1612 EX15 2 Novel
S/L1684 5262C/T EX15 2 Novel
5383C/T A1724 EX15 14 [16]
5518C/T H1769 EX15 2 Novel
5584C/T N1791 EX15 2 Novel
5665G/A A1818 EX15 10 Novel
5893C/T A1894 EX15 2 Novel
5974G/A L1921 EX15 2 [16]
V/I1943 6038G/A EX15 2 Novel
6667C/T D2152 EX15 2 Novel
IVS1522C/T IVS15 2 Novel
7138C/T G2309 EX16 4 [9]
7376T/C L2389 EX17 25 [15]
7652C/T L2481 EX18 21 [15]
IVS2047T/G IVS20 19 Novel
H/R2638 8024A/G EX21 8 [15]
P/S2674 8231C/T EX22 2 [9]
T/M2708 8334C/T EX22 2 [9]
IVS228G/A IVS22 2 [15]
G/R2814 8650G/A EX23 6 [9]
8650C/T L2816 EX23 4 [9]
S/L2958 9084C/T EX24 2 Novel
T/N2977 9141C/A EX24 2 Novel
V/M3057 9380G/A EX25 2 Novel
9541C/T P3110 EX26 14 [13]
IVS27-13T/C IVS27 2 Novel
9880G/A T3223 EX28 2 [13]
10168C/T S3319 EX30 2 Novel
IVS30-25G/A IVS30 2 Novel
R/Q3434 10512G/A EX33 2 Novel
A/V3511 10743C/T EX35 16 [13]
IVS3742delTT IVS37 4 Novel
IVS3813A/G IVS38 6 [35]
11554C/T D3781 EX40 2 Novel
IVS415ins3 IVS41 2 Novel
11890C/T S3893 EX42 4 Novel
12169C/T A3986 EX43 2 Novel
12184C/G A3991 EX43 2 [35]
I/V4044 12341A/G EX44 23 [41]
IVS43-34C/A IVS43 10 Novel
A/V4058 12384C/T EX45 2 [41]
12484A/G A4091 EX45 6 [36]
P/S4123 12578C/T EX45 2 Novel
12617C/T L4136 EX45 2 [35]
V/I4145 12645G/A EX45 2 [42]
S/F4189 12777C/T EX46 2 Novel
12838C/T P4209 EX46 23 [13]
13135G/A (3 UTR) EX46 2 Novel
PKD2
R/P28 83G/C EX1 5 [12]
IVS3-23G/A IVS3 25 [11]
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was analyzed, an average of 5.4 changes were detected, flecting the approximately 10% of mutations to the
PKD2 gene detected in this typical ADPKD population.indicating that the ratio of polymorphic changes to muta-
tion is very high at 4:1 to 5:1. The problem of common If all the possible missense changes also are considered
as mutations, the detection rate rises to 76% and is com-polymorphism was overcome to some extent by using
the reproducible shape of the DHPLC profile to identify parable to comprehensive screens of other large genes
associated with disorders with genetic and allelic hetero-the change without sequencing (“signature-based” geno-
typing). Furthermore, because of the change specific geneity, such as tuberous sclerosis or Alport syndrome
[32, 39]. The undetected changes presumably consist ofshape of the profile, we did not find that common poly-
morphisms masked other mutations. When a mutation more subtle splicing defects (caused by changes away
from the donor and acceptor splicing sites and by silentand polymorphism were detected in the same fragment
a novel profile was generated. exonic changes), promoter mutations and the likelihood
of a low level of changes undetected by DHPLC. In ad-The difference in the rate of polymorphism between
PKD1 and PKD2 was striking in this study, with only two dition, larger rearrangements of PKD2 were not sought
and the possibility that some of these cases may be due topolymorphisms detected in PKD2. Although it is possi-
ble that there are special reasons for the level of changes as yet unmapped ADPKD genes should be considered.
As in previous studies, mutations were spread through-at PKD1 (such as the polypyrimidine tract in IVS21 [37]
or conversion by HG changes [14]) the GC rich nature out the PKD1 and PKD2 genes and, except for one case,
were unique to a single family within the study [9]. How-of PKD1 is probably the major explanation. The GC rich-
ness results in a high level of CpG dinucleotides that are ever, with the accumulating data on mutations, it is in-
teresting to see that five changes matched previouslyknown to be hot spots for mutation because the methyl-
ated cytosine is susceptible to spontaneous deamination described mutations (Table 4). Even if all the putative
substitutions are included as mutations the majority ofto thymine [38]. Although this change only accounted
for 4 of 20 mutation-associated substitutions in PKD1, changes (82%) were clear truncating or substantial in-
frame changes, likely to inactivate the gene. This finding54% of substitution polymorphisms occurred at CpG di-
nucleotides. An influence of the unusual IVS21 sequence is of importance in the diagnostic setting indicating that,
despite the problem differentiating missense mutationswas not clear, as changes were found throughout the gene
and no mutations and only 8 of 70 polymorphisms matched and neutral polymorphisms, clear results of mutation de-
tection could be reported in 64% of cases. We had pre-known HG sequences. The large size of the PKD1 tran-
script also may partly explain the higher level of poly- viously estimated from sequencing small regions of PKD1
that missense mutations would represent a higher levelmorphism (a target four times greater than PKD2).
The high level of polymorphic change at PKD1 makes of mutations [9], but that has not been borne out by this
study. It remains possible, however, that missense muta-it difficult to determine if a missense substitution is a
mutation. Tests of whether the change is conservative tions in highly conserved regions of the protein will be
important sites of mutation. The nature of the detectedand if the residue is conserved in polycystin-1 orthologs
seems to be of only limited value as some of the polymor- changes is consistent with cyst development being associ-
ated with polycystin loss, through a two-hit mechanismphisms also appear to be non-conservative and some are
at conserved sites [9]. Segregation with the disease is an [40], or haploinsufficiency. Despite the evidence that mu-
tations may inactivate, it will be interesting to see if anyimportant test, as lack of co-inheritance rules out the
change as a mutation, as long as the diagnosis in other significant correlations with phenotype are associated
with the type and/or position of mutations. Such studiesfamily members is clear. Therefore, even within a routine
molecular diagnostic setting, the availability of at least should now be possible with this improved and simplified
mutation screening approach.one sample from another affected family member would
be beneficial. Of course, segregation with the disease is We have illustrated the possibilities for routine molec-
ular diagnosis in ADPKD by direct mutation detectionnot proof that the missense change is a mutation, but
hopefully as more molecular screening of PKD1 is re- using DHPLC. Genetic diagnosis is likely to become in-
creasingly important as potential therapies become avail-ported, it will be possible to assemble lists of segregating
mutations and non-segregating polymorphisms. The dif- able, to determine the status of at-risk individuals at an
early stage before significant renal damage has occurred.ficulties associated with missense changes are, however,
likely to remain a complication of analysis at this locus
until a functional test for the protein is available. ACKNOWLEDGMENTS
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